Soc. Generale Call 200 AMGN 20.12.../ DE000SV47584 /
14/06/2024 09:05:56 | Chg.-0.22 | Bid07:55:10 | Ask07:55:10 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
9.34EUR | -2.30% | 9.42 Bid Size: 1,000 |
- Ask Size: - |
Amgen Inc | 200.00 USD | 20/12/2024 | Call |
GlobeNewswire
30/05
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affa...
GlobeNewswire
28/05
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
GlobeNewswire
27/05
Samsung Bioepis Announces Oral Presentation on Switching Period Results for SB16, a Proposed Biosimi...
GlobeNewswire
23/05
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...
GlobeNewswire
22/05
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
21/05
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire
21/05
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a bios...
GlobeNewswire
15/05
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
GlobeNewswire
14/05
Accumulus Synergy Sponsors Revolutionary Healthcare Data Standard, Advancing Towards Global Dossier
GlobeNewswire
14/05
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
13/05
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
09/05
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/05
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
08/05
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update